Jaguar Health

191 articles about Jaguar Health

• Jaguar Health Receives Positive Nasdaq Listing Determination

  10/29/2020

  Jaguar Health, Inc. announced that on October 28, 2020 the Company received formal notice that the Nasdaq Hearings Panel granted Jaguar an extension through December 23, 2020 to evidence compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

• Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 16, 2020

  10/16/2020

  Jaguar Health, Inc. announced that effective October 13, 2020, the Company has granted nonstatutory stock options for the purchase of up to 45,000 shares of the Company's common stock to one new employee as inducement awards under the Company's Inducement Award Plan.

• Jaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs & Quality Assurance

  10/14/2020

  Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy

• Jaguar Health Provides Updates Regarding Company Capitalization Strategy

  10/13/2020

  Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million

• Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

  10/7/2020

  Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total Potential of $17 Million

• Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications

  10/6/2020

  Financial Condition for Initial $5 Million Tranche of Potential $16 Million Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann

• Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million

  10/1/2020

  Proceeds Will Be Allocated to Support Regulatory Activities Associated with the Company's Development Pipeline, Including Funding the Pivotal Clinical Trial for Mytesi for Cancer Therapy-Related Diarrhea (CTD)

• Jaguar Health to Host Exclusive Virtual Educational Event “Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer”

  9/24/2020

  Jaguar Health, Inc. (NASDAQ:JAGX), a commercial stage pharmaceuticals company focused on discovering, developing, and commercializing novel, plant-based, non-opioid, and sustainably derived prescription medicines, today announced it will hold its first "Diarrhea Dialogues" virtual event on October 20 from 3:00 PM to 4:30 PM ET.

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative

  9/16/2020

  Jaguar Health announced today the formation of a scientific strategy team (SST) to support the company's recently launched mental health,

• Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16

  9/11/2020

  Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte, Jaguar's founder, president and CEO, will present at the virtual 2020 H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020, at 3:00 p.m. Eastern Time.

• Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020

  9/10/2020

  Jaguar Health, Inc.today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company") have jointly entered into a third amendment to the accounts receivable purchase agreement with Oasis Capital

• Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants

  9/3/2020

  Jaguar announced today the launch of its mental health Entheogen Therapeutics Initiative (ETI) that aims to discover and develop groundbreaking, novel, natural medicines derived from psychoactive plants for treatment of mood disorders, neuro-degenerative diseases, addiction, and other mental health disorders.

• Jaguar Health Completes Transactions that Increase Stockholders' Equity Above $5,000,000

  9/2/2020

  Amount Exceeds Minimum Stockholders' Equity Requirement for Initial Listing on The Nasdaq Capital Market

• Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi)

  8/19/2020

  Jaguar Health, Inc. today provided updates regarding ongoing investigator-initiated trials in non-HIV patient populations of crofelemer (Mytesi®), the novel FDA-approved plant-based oral drug developed and marketed by Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.

• Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs

  8/18/2020

  Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) the last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs.

• Company Update,Financing

  8/14/2020

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., have jointly entered into a second amendment to the accounts receivable purchase agreement with Oasis Capital, LLC dated May 12, 2020, pursuant to which Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company.

• Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results

  8/13/2020

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated second quarter 2020 financial results.

• Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates

  8/11/2020

  Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea

• Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea

  8/6/2020

  Jaguar Health, Inc. announced the activation of the investigational new drug (IND) application filed by the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc. ("Napo") with the FDA for the use of crofelemer (Mytesi®) for prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.